We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Sunday
May 04
10:30 - 11:30
Stolz 1
Upper GI 2
Fatjona Kraja, Albania;
Florence Huguet, France
Mini-Orals are presented at one of the sessions scheduled in the two mini-oral theatres. Each author will present a 4-slide PowerPoint orally for 4 minutes, followed by 3 minutes for discussion. Sessions will be recorded and made available via the online platform and mobile app.
Mini-Orals
Clinical
GI
10:30 - 10:37
Radical hypofractionated radiotherapy with capecitabine for unfit esophageal cancer patients: a phase II study (CRADLE / NL75846.029.20).
Leigh Bruijs, The Netherlands
E25-2501
10:37 - 10:44
Dosimetric effects of respiratory and anatomical changes in the European PROTECT trial: Proton vs photon therapy in locally advanced esophageal cancer
Sarah Eckholdt Jensen, Denmark
E25-3314
10:44 - 10:51
Nationwide photon radiotherapy planning study for oesophageal cancer
Sabine Visser, The Netherlands
E25-3909
10:51 - 10:58
Development and multicentre validation of an NTCP-model for pneumonia in oesophageal cancer patients after neoadjuvant chemoradiotherapy and surgery
Mark Frederiks, The Netherlands
E25-2026
10:58 - 11:05
Immunomodulatory effects of SBRT in primary liver cancer patients: Results from the LAPIS study
Eleni Gkika, Germany
E25-4285
11:05 - 11:12
Predicting Survival in Pancreatic Cancer: Insights from Systemic Inflammatory Scores
Ece Ercan, Turkey
E25-3951
11:12 - 11:19
Determining the maximum tolerated dose of MR-guided radiotherapy for (peri)pancreatic tumors (RadioPanc): a phase I dose escalation trial
Guus Grimbergen, The Netherlands
E25-1219
11:19 - 11:26
Clinical outcomes from EMERALD trial: A phase I evaluating ultra-hypofractionated MR-Guided Adaptive SABR (SMART) for localized pancreatic cancer.
Somnath Mukherjee, United Kingdom
E25-1994